-+ 0.00%
-+ 0.00%
-+ 0.00%

The Zhitong Finance App learned that the experimental multiple sclerosis drug from Sanofi (SNY.US) experienced a double setback on Monday: regulatory delays in the US occurred, and at the same time, a late-stage clinical trial failed.

Zhitongcaijing·12/15/2025 11:09:08
Listen to the news
The Zhitong Finance App learned that the experimental multiple sclerosis drug from Sanofi (SNY.US) experienced a double setback on Monday: regulatory delays in the US occurred, and at the same time, a late-stage clinical trial failed.